A specialist NHP CRO for translational drug development
Prisys Biotech (PRISYS) is a Shanghai-based contract research organization (CRO) supporting preclinical drug development and translational research. We work with biopharmaceutical companies, pharmaceutical companies, research institutions, and biomedical researchers worldwide. Our work focuses on non-human primate (NHP) technology, NHP disease models, and fit-for-purpose study designs that help connect nonclinical research with clinical development.
PRISYS provides integrated preclinical research services across multiple stages of drug development. These services include nonclinical proof-of-concept studies, NHP model-based efficacy studies, pharmacokinetic and pharmacodynamic studies (PK/PD), toxicology, safety evaluation, and customized translational research.
Our study designs are developed around the needs of each research program, including the mechanism of action, target biology, disease model, route of administration, evaluation endpoints, and development decision to be supported.
Prisys Biotechnologies: General Introduction
What does an NHP-focused contract research organization actually do, and where does it fit in preclinical drug development?
This short introduction to Prisys Biotechnologies (PRISYS) covers our non-human primate (NHP) research platform in Shanghai, the translational programs we run for biopharmaceutical partners worldwide, and how our scientific teams work with sponsors – from study design and model selection through to data reporting.
What the video covers:
- Who we are: a contract research organization specialized in NHP translational research
- Our research platform: animal welfare, imaging, surgery, dosing and bioanalysis capabilities
- How we work with sponsors: fit-for-purpose study design, direct scientific communication and transparent reporting
- The programs we support: NHP disease models, gene therapy and gene editing, ophthalmology, PK/PD and ADME, safety evaluation
- Where we are based: Shanghai, China, working with partners across the US, Europe and Asia
For more information about Prisys Biotechnologies and our NHP translational research capabilities, please contact: bd@prisysbiotech.com.
Our research platform
PRISYS combines specialized NHP technology platforms, industrial-scale research facilities, and an experienced scientific team to support complex preclinical studies. Our translational capabilities include clinical imaging, targeted organ drug delivery, and AI-based NHP behavior analysis.
Our core capabilities include:
- NHP pharmacology and disease model research
- NHP model-based efficacy studies
- Pharmacokinetic and pharmacodynamic studies (PK/PD)
- Customized studies for biopharmaceutical development
This integrated approach allows research teams to evaluate drug candidates in clinically relevant NHP models and generate data for further development and clinical planning.
Vision: Better Human Health by Primate Translational Sciences
We aspire to be the innovator in non-human primate disease modeling and the capstone platform with global innovation-centered collaborations, delivering more translational science and transformational technologies for new medicine.
Mission: Solidifying Innovations of New Medicine
Our mission is to help researchers generate reliable and decision-relevant evidence for new medicines.
We do this by:
- Developing and applying clinically relevant NHP disease models
- Designing studies that address specific drug development questions
- Supporting pharmacology, PK/PD, toxicology, and safety evaluation
- Applying translational technologies to improve the interpretation of nonclinical data
Quality and animal welfare
PRISYS has achieved full accreditation from AAALAC International, an internationally recognized program for the assessment and accreditation of animal care and use programs in research.
The accreditation reflects the standards of PRISYS' animal care and use program. It supports our commitment to humane animal care, ethical oversight, veterinary management, and the responsible use of research animals.
Animal welfare is an integral part of our research operations. Our studies are designed and conducted with appropriate attention to animal care, scientific necessity, and the principles of responsible research.
Working with PRISYS
PRISYS supports research teams that require specialized NHP capabilities for preclinical and translational studies. Whether a program requires an NHP disease model, an integrated PK/PD study, a safety evaluation, or a customized translational research plan, our team works with clients to define the scientific objectives, study design, evaluation strategy, and project deliverables.
Planning an NHP preclinical study?
Talk with the PRISYS team about your disease model, study objectives, PK/PD requirements, safety evaluation plan, or translational research needs.
Frequently asked questions
Q: What is Prisys Biotech?
A: Prisys Biotech is a Shanghai-based preclinical contract research organization (CRO) specializing in non-human primate (NHP) research, disease models, pharmacology, PK/PD, toxicology, safety evaluation, and translational drug development.
Q: What preclinical services does PRISYS provide?
A: PRISYS provides NHP pharmacology, NHP disease model studies, efficacy evaluation, PK/PD studies, toxicology, safety evaluation, and customized translational research for biopharmaceutical development.
Q: Why is PK/PD analysis important in preclinical drug development?
A: PK describes drug exposure, while PD describes the biological response. Linking the two helps determine whether changes in pharmacological activity are associated with drug exposure and provides a quantitative basis for dose and regimen evaluation.
Q: What is PRISYS known for?
A: PRISYS is known for its specialized NHP research platform, NHP disease models, integrated preclinical study capabilities, and translational technologies designed to support the development of new therapeutics.
Q: Where is Prisys Biotech located?
A: Prisys Biotech is located in Shanghai, China, and provides services to biopharmaceutical and biomedical research teams worldwide.
